Biogen Inc. has agreed to acquire Apellis Pharmaceuticals Inc. for $5.6 billion, expanding its treatments in immunology and rare diseases in one of the company’s largest-ever acquisitions.
www.bloomberg.com
#Biogen #Buy #Apellis #Billion #Boost #Kidney #Franchise
Biogen to Buy Apellis for $5.6 Billion to Boost Kidney Franchise
